Concorde International reports FY24 EPS ($5.08) vs $9.61 last year
Financial Performance: Concorde reported FY24 revenue of $10.49 million, a slight decrease from $10.66 million the previous year.
IPO Achievement: The company successfully completed its IPO on April 22, 2025, raising $5.75 million in gross proceeds and starting trading on the Nasdaq Capital Market, which supports its growth strategy.
Trade with 70% Backtested Accuracy
Analyst Views on CIGL
About CIGL
About the author
Concorde International Group Achieves 11% Yearly Revenue Increase, Reaching $6.0 Million in H1 2025
Financial Performance: Concorde International Group Ltd. reported a 30% increase in gross profit to $1.9 million for H1 2025, with revenue rising approximately 11% to $6.0 million compared to H1 2024.
Gross Margin Improvement: The company's gross margin improved by 450 basis points to 31.5% in H1 2025, up from 27.0% in the previous year, indicating enhanced operational efficiency.
Future Growth Strategy: The company plans to expand internationally into Malaysia, Australia, and North America, leveraging partnerships and its recent acquisition of Software Risk's assets to enhance its technology portfolio.
Operational Loss: Despite the revenue growth, Concorde reported an operating loss of approximately $2.5 million in H1 2025, a significant improvement from an operating loss of $83.3 million in H1 2024, which was affected by a one-time share-based compensation expense.
Concerns Rise Over Pump-and-Dump Scams Amid Penny Stock Selloffs - Report
Investors Lose Billions: U.S.-listed Chinese stocks experienced significant declines, losing a combined $3.7 billion in market value after being promoted on social media, raising concerns about potential pump-and-dump scams.
Affected Stocks: Seven specific stocks, including Concorde International and Ostin Technology, saw their values drop by over 80% following social media promotions, although there is no evidence that the companies were involved in these stock movements.
FBI Warning: The FBI reported a 300% increase in complaints related to ramp-and-dump stock fraud, highlighting that investors are often targeted through social media advertisements promoting fake investment clubs.
Regencell Bioscience Surge: Regencell Bioscience's shares surged nearly 10,000% year-to-date, with analysts warning it may follow a boom-and-bust pattern similar to other Chinese stocks, despite no indication of company involvement in unusual trading activity.
